Research programme: anthrax toxin inhibitors - Biophage Pharma/University of Toronto
Latest Information Update: 06 Jun 2007
At a glance
- Originator Biophage Pharma; University of Toronto
- Mechanism of Action Anthrax toxin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Anthrax
Most Recent Events
- 06 Jun 2007 Preclinical development is ongoing
- 01 Mar 2002 Preclinical trials in Anthrax in Canada (unspecified route)